A preclinical-only peptide with high local bioactivity, rapid degradation, and critical knowledge gaps for anyone considering use

Introduction

IGF-1 DES—formally designated as Des(1-3) IGF-1—is a naturally occurring, N-terminally truncated variant of insulin-like growth factor 1, missing the first three amino acids of the native peptide (glycine, proline, and glutamic acid). Discovered in bovine and human brain tissue, it represents a fundamentally different pharmacological entity from both native IGF-1 and the widely discussed IGF-1 LR3 analogue.

The defining characteristic of IGF-1 DES is its dramatically reduced binding affinity for insulin-like growth factor binding proteins (IGFBPs)—particularly IGFBP-3 and IGFBP-5. This truncation impairs the N-terminal epitope critical for IGFBP interaction, resulting in a peptide that circulates with minimal buffering. The consequence is paradoxical: despite higher potency per molecule at the IGF-1 receptor in certain bioassays (up to 10-fold), DES exhibits a severely compressed half-life—approximately 20 to 30 minutes in circulation—compared to native IGF-1’s 12-to-15 hour IGFBP-protected lifespan.

In research and community contexts, IGF-1 DES is employed primarily as a site-specific injection—administered directly into target muscle tissue—with the hypothesis that local, brief IGF-1R activation may trigger myogenic signaling and hyperplasia. No human clinical trials exist; all evidence is preclinical or observational. WADA prohibits it under the S2 anabolic agent category. The FDA has not approved it and has no active development pathway.

This article synthesizes the known science, critically examines claims, and outlines the realistic safety and regulatory landscape. It is intended for researchers, informed athletes, and healthcare providers seeking evidence-based context rather than advocacy.

Quick Facts

What Is IGF-1 DES?

IGF-1 DES is a truncated variant of IGF-1, created by removal of the N-terminal tripeptide (Gly-Pro-Glu) from the native 70-amino-acid sequence, yielding a 67-amino-acid peptide spanning positions 4–70 of the original molecule. This simple deletion has outsized biochemical consequences.

Structural Basis

The N-terminal region of IGF-1 is the primary epitope for high-affinity binding to IGFBPs, especially IGFBP-3 and IGFBP-5. In the native peptide, this region mediates a nearly irreversible ternary complex with the acid-labile subunit (ALS), forming a ~150 kDa reservoir that prolongs half-life and regulates tissue availability. The loss of Gly-Pro-Glu eliminates or severely impairs this binding interface. The consequence: IGF-1 DES circulates largely unbound or loosely bound, rendering it vulnerable to rapid enzymatic degradation and glomerular filtration.

Paradoxically, the same truncation that shortens half-life enhances per-molecule bioactivity at the IGF-1 receptor (IGF-1R). In cell-based bioassays, IGF-1 DES demonstrates 3- to 10-fold greater potency than native IGF-1 at stimulating phosphorylation of IGF-1R and downstream signaling (e.g., AKT, mTOR). The mechanism remains incompletely understood; possibilities include reduced sequestration by soluble or membrane-associated IGFBPs and a possible subtle conformational difference that modulates receptor binding kinetics.

Why It Exists in Nature

IGF-1 DES is not a synthetic creation; it is a naturally occurring variant detected in brain tissue of multiple species (bovine, human, porcine, etc.). Its physiological role remains unclear. Some researchers speculate it may serve as a local, short-acting growth signal in neural development or plasticity; others suggest it is a proteolytic byproduct of IGF-1 metabolism with no discrete function. The fact that it circulates endogenously does not confer safety; many endogenous molecules are toxic at elevated concentrations.

Origins and Discovery

The identification of IGF-1 DES dates to the 1990s and early 2000s, emerging from detailed structural and biochemical analyses of IGF-1 variants in mammalian tissues, particularly the central nervous system. Research groups in Europe and North America characterized it as a naturally occurring N-terminal truncation, distinct from other IGF-1 variants like MGF (mechano growth factor) and IGF-1 LR3.

Early Research Context

The discovery coincided with increased interest in IGF-1 peptide biology beyond the canonical endocrine axis. While circulating IGF-1 is primarily synthesized in the liver and regulated by growth hormone, local IGF-1 production in muscle, bone, and neural tissue was recognized as critical for tissue-specific growth and repair. The identification of IGF-1 DES suggested that cells and tissues might preferentially generate or accumulate shorter-lived, locally active IGF-1 variants under specific conditions (e.g., muscle injury, neural remodeling).

Unlike IGF-1 LR3—a deliberately engineered analogue created to enhance systemic circulation and evade IGFBP binding—IGF-1 DES was discovered as an endogenous form. This distinction led some researchers and practitioners to view it as “more natural” than analogues. However, the endogenous presence of a substance does not equate to safety or efficacy when administered exogenously at pharmacological doses.

Preclinical Characterization

By the early 2010s, several in vitro and animal model studies had characterized IGF-1 DES’s binding kinetics, potency at IGF-1R, and effects on myogenic cell differentiation and protein synthesis in muscle tissue. The consensus findings were: (1) dramatically reduced IGFBP binding; (2) enhanced per-molecule IGF-1R bioactivity in cultured cells; (3) rapid degradation in serum; and (4) local anabolic effects when injected directly into muscle. No Phase 1 human trials were initiated, and IGF-1 DES never entered the clinical development pipeline.

Mechanism of Action

IGF-1 Receptor Signaling

Like all IGF-1 variants, IGF-1 DES exerts its primary biological effects by binding to and activating the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase. Upon ligand binding, IGF-1R undergoes autophosphorylation, recruiting and activating downstream signaling proteins, principally insulin receptor substrate-1 (IRS-1) and phosphoinositide 3-kinase (PI3K). This initiates two major intracellular cascades:

PI3K-AKT-mTOR pathway: Drives protein synthesis, lipid synthesis, and cell survival through mTORC1 activation. This is the primary pathway underlying muscle hypertrophy and metabolic anabolism.

MAPK-ERK pathway: Mediates cell proliferation, differentiation, and survival signaling. In myogenic cells, this pathway supports satellite cell activation and fusion into myofibers.

In vitro, IGF-1 DES activates both pathways with greater per-molecule potency than native IGF-1, manifesting as more robust dose-dependent phosphorylation of AKT and ERK at lower peptide concentrations. The enhanced potency is likely attributable to reduced sequestration by IGFBPs and possibly subtle differences in receptor binding kinetics.

IGFBP Displacement and Clearance

The key mechanistic difference between IGF-1 DES and native IGF-1 is its interaction—or lack thereof—with IGFBPs. Native IGF-1 binds IGFBP-3 and IGFBP-5 with dissociation constants (Kd) in the picomolar to nanomolar range, forming tight, long-lived complexes. IGF-1 DES exhibits Kd values in the nanomolar to micromolar range for the same IGFBPs, representing a 1,000-fold or greater reduction in binding affinity.

This impaired binding has two physiological consequences:

(1) Enhanced bioavailability: A larger proportion of circulating IGF-1 DES is “free” (unbound) and available to bind to cell surface IGF-1R. Estimates suggest 50–90% of IGF-1 DES may circulate free, versus <1% for native IGF-1.

(2) Accelerated clearance: Unbound peptide is rapidly attacked by proteases and eliminated by the kidney, resulting in the short 20–30 minute half-life. In contrast, IGFBP-bound native IGF-1 is protected from degradation and has a half-life of 12–15 hours.

For systemic IGF-1 (delivered intravenously or subcutaneously to achieve high circulating levels), this short half-life is a major drawback—it necessitates frequent dosing to maintain exposure. However, for local intramuscular injection (the proposed application), the short half-life is arguably a feature: it concentrates bioactivity in the injection site and minimizes systemic spillover and potential systemic adverse effects.

Local vs. Systemic Pharmacology

The theoretical advantage of IGF-1 DES over native IGF-1 or IGF-1 LR3 is site-specific deployment. When injected directly into a target muscle, high local concentrations of IGF-1 DES rapidly activate myogenic signaling—promoting satellite cell mobilization, protein synthesis, and possibly myonuclei accretion. The peptide is then quickly degraded by local proteases and cleared, minimizing systemic exposure and downstream risk of off-target growth signaling (e.g., in cancer-prone tissues).

This reasoning is sound in principle, but empirical validation in humans is absent. The extrapolation from in vitro cell culture and animal models to human muscle tissue in vivo remains speculative.

Key Research Areas

Myogenic Differentiation and Satellite Cell Activation

In vitro studies demonstrate that IGF-1 DES promotes the differentiation of myogenic precursor cells (myoblasts) into mature myotubes more potently than native IGF-1. In addition, IGF-1 DES activates p38 MAPK and other signaling nodes implicated in satellite cell (muscle stem cell) expansion and quiescence exit. Animal studies (primarily in rodents) show that intramuscular IGF-1 DES injection increases local myonuclei content and muscle fiber cross-sectional area, suggesting a hyperplastic effect (actual increase in fiber number rather than simple hypertrophy).

The hypothesis underlying community use—that local IGF-1 DES induces lasting myonuclei gains that persist after the peptide is cleared—is derived from this preclinical literature. However, this extrapolation has not been prospectively validated in humans.

IGF-1R Signaling Kinetics

Detailed receptor binding and phosphorylation kinetics studies have characterized how IGF-1 DES compares to native IGF-1 and other analogues. Key findings include superior sustained phosphorylation of AKT and mTOR at lower peptide concentrations, and possibly differential kinetics of receptor internalization and recycling. These mechanistic details inform understanding of why DES exhibits higher per-molecule potency but do not directly translate to in vivo efficacy or safety in humans.

Metabolic and Immune Considerations

Limited preclinical work has examined IGF-1 DES’s effects on glucose homeostasis, lipid metabolism, and immune function. Native IGF-1 at pharmacological concentrations can trigger hypoglycemia via enhanced glucose uptake and reduced hepatic glucose output. IGF-1 DES, given its higher bioactivity, might provoke similar or greater metabolic derangements, but this has not been studied in controlled human settings. Similarly, the pro-growth signaling triggered by IGF-1 DES could theoretically enhance immune cell proliferation and function or, conversely, promote chronic inflammation; the net effect is unknown.

Common Claims versus Current Evidence

Human Evidence Landscape

The evidence base for IGF-1 DES in humans is zero. No peer-reviewed clinical trials, observational cohort studies, or case series on IGF-1 DES use in athletes or patients have been published in medical literature.

Published Literature

A PubMed search for “IGF-1 DES” or “Des(1-3) IGF-1” in 2025 returns approximately 15–20 peer-reviewed publications, nearly all focused on biochemical characterization, receptor binding kinetics, or rodent/cell-based studies. Roughly zero address clinical efficacy or safety in humans. Some general IGF-1 peptide reviews mention IGF-1 DES in passing as a “preclinical tool” but do not recommend human use.

Community Reports

In online forums and performance-enhancement communities, anecdotal reports of IGF-1 DES use exist, typically describing intramuscular injection into target muscles (e.g., arms, chest, shoulders) with claims of enhanced local muscle growth, improved vascularity, and minimal systemic effects. These reports are uncontrolled, often lack baseline measurements or control groups, and cannot distinguish between placebo effects, concomitant training intensity, diet, or other concurrent compounds. Some reports mention local redness, swelling, or discomfort at the injection site; a few describe fatigue or transient hypoglycemia. The heterogeneity and lack of standardization make generalization impossible.

In sum, the human evidence landscape is indistinguishable from empty.

Safety, Risks, and Limitations

IGF-1 Axis–Related Risks

IGF-1 DES, like any IGF-1 agonist, poses inherent risks stemming from activation of the IGF-1 receptor signaling axis. These include:

Hypoglycemia: IGF-1 drives glucose uptake in skeletal muscle and suppresses hepatic glucose output. At pharmacological doses, this can precipitate symptomatic hypoglycemia, particularly in fasted or post-exercise states. The risk is theoretically heightened for IGF-1 DES given its higher per-molecule bioactivity, but has never been quantified in humans.

Carpal tunnel syndrome and joint pain: Native IGF-1 at therapeutic doses (and at higher supraphysiologic levels) is associated with carpal tunnel syndrome, arthralgia, and myalgia. The mechanism likely involves connective tissue growth and edema. IGF-1 DES might provoke similar or greater local effects given higher bioactivity, although local injection theoretically minimizes systemic manifestations.

Proliferative signaling in non-target tissues: Despite local injection, some IGF-1 DES will inevitably enter the bloodstream. IGF-1R signaling promotes proliferation in multiple tissues, including adipose tissue, bone, and potentially cancer-prone epithelial tissues. Chronic or repeated exposure to elevated IGF-1 signaling is associated with increased cancer risk in epidemiological studies (though causality is debated). The long-term safety of repeated IGF-1 DES dosing is completely unexplored.

Edema and water retention: IGF-1 promotes sodium retention and fluid expansion. Local injection is unlikely to cause systemic edema, but subcutaneous or intravenous administration would risk significant fluid retention and hypertension.

Injection-Related Risks

Intramuscular injection carries mechanical and infectious risks independent of the compound’s pharmacology:

Infection: Non-sterile injection technique or contaminated peptide supplies can lead to localized abscess, myositis, or systemic bacteremia. Self-administration significantly elevates this risk.

Nerve or vessel injury: Incorrect injection technique can damage nerves (e.g., radial nerve in the arm) or arteries, leading to acute pain, paresthesia, or limb-threatening hemorrhage. This is particularly concerning when self-injecting into small muscle compartments.

Local tissue damage: Repeated injection into the same site risks fibrosis, calcification, and functional impairment. The low pH of some peptide formulations and the irritant properties of the peptide itself can trigger local inflammation, necrosis, or abscess formation.

Quality, Purity, and Identity Issues

IGF-1 DES is not manufactured under FDA or EU regulatory oversight; suppliers are typically unregulated research chemical vendors. Risks include:

Identity uncertainty: The peptide may not be IGF-1 DES; it could be mislabeled native IGF-1, a different truncated variant, or an entirely different compound. Chromatographic or mass spectrometry verification is rarely performed by end users.

Impurity and endotoxin contamination: Bacterial endotoxins, residual solvents, or process impurities can trigger local or systemic inflammatory responses, fever, or sepsis.

Aggregation: Peptides are prone to aggregation during storage or reconstitution. Aggregates may elicit immune responses (antibody formation) or cause mechanical emboli if injected intravenously.

Lack of stability data: While lyophilized peptides are generally stable at 2–8°C (35–46°F) for 1–2 years, vendor-provided stability data is often minimal or absent. Room-temperature or improperly stored peptides may degrade, yielding fragments with unknown activity or toxicity.

Knowledge Gaps

Critical unanswered questions render an accurate risk-benefit calculation impossible:

• What is the systemic pharmacokinetic and pharmacodynamic profile of IGF-1 DES in humans?
• What fraction of locally injected IGF-1 DES enters the bloodstream, and over what timescale?
• Does local IGF-1 DES injection produce lasting myonuclei gains and durable muscle growth in humans?
• What is the risk of hypoglycemia at typical community doses?
• Does repeated IGF-1 DES administration increase cancer risk?
• What is the incidence of injection site complications (infection, abscess, nerve damage)?
• Are there long-term metabolic, endocrine, or immune consequences of chronic use?

Absent controlled human data, all statements about safety and efficacy are speculative.

Legal and Regulatory Status

WADA (World Anti-Doping Agency)

IGF-1 DES is explicitly prohibited under WADA’s Prohibited List, categorized under S2 (Peptides, Growth Factors, Related Substances, and Mimetics). The WADA Code defines S2 as including “growth factors and their releasing factors, including growth hormone (GH), insulin-like growth factors (IGF-1, IGF-2), and mechano growth factor (MGF).”

IGF-1 DES, as a truncated IGF-1 variant, unambiguously falls within this definition. Use of IGF-1 DES in athletes competing under WADA jurisdiction—including all Olympic sports, professional cycling, track and field, and many others—constitutes doping and carries sanctions including disqualification, bans, and loss of competitive results.

Detection of IGF-1 DES in urine or blood samples may be challenging because: (1) its rapid clearance limits window of detection; (2) its amino acid sequence is similar to endogenous IGF-1, making immunoassay distinction difficult; and (3) routine anti-doping laboratories do not routinely test for it. However, advanced techniques (e.g., isotope ratio mass spectrometry, proteomics) could theoretically detect DES if specifically targeted.

FDA (U.S. Food and Drug Administration)

IGF-1 DES is not approved as a drug by the FDA. No Investigational New Drug (IND) applications or active clinical development programs are known. It is not marketed as a pharmaceutical product in the United States. Possession without a license is illegal; distribution is illegal. IGF-1 DES is available only through unregulated suppliers, typically labeled “for research purposes only” as a circumvention of regulation.

European Union

Similar to the FDA, the European Medicines Agency (EMA) has not approved IGF-1 DES. It is not available as a licensed pharmaceutical. EU member states classify peptides like IGF-1 DES variously; some treat them as prescription-requiring biologics, others as unscheduled research chemicals. This patchwork creates legal ambiguity but does not confer legitimacy or safety.

Non-WADA Jurisdictions

Athletes competing in non-WADA sports (e.g., bodybuilding, CrossFit, some powerlifting federations) may not face WADA sanctions for IGF-1 DES use, but they remain subject to national laws. In most countries, self-administration of unlicensed biopharmaceuticals is either explicitly prohibited or falls into legal gray zones.

Research Protocols

Preclinical In Vitro Studies

Standard protocols for evaluating IGF-1 DES efficacy and safety in cell culture include:

Preclinical In Vivo (Animal) Studies

Dosing in Published Research

Dosing in Self-Experimentation

Disclaimer: The following table summarizes self-reported dosing practices from online communities and anecdotal reports. These are not recommendations and do not imply efficacy, safety, or legality. Actual community practices are highly variable and poorly documented.

Frequently Asked Questions

Related Peptides and Comparisons

IGF-1 DES vs. IGF-1 LR3 (Long-Arg3 IGF-1)

IGF-1 DES vs. MGF (Mechano Growth Factor)

MGF is an alternative IGF-1 splice variant (IGF-1 Ec) that is induced by mechanical loading and is thought to drive local muscle adaptation to training. Unlike IGF-1 DES, MGF is a distinct protein (12 amino acids) generated by alternative splicing of the IGF-1 gene. MGF also exhibits reduced IGFBP binding and a short circulating half-life. The theoretical rationale for MGF and IGF-1 DES is similar (local, transient myogenic signal), but they are distinct molecules with different signaling properties. MGF is even less studied in humans than IGF-1 DES, and the evidence tier is similarly preclinical-only.

IGF-1 DES vs. Native IGF-1

The key advantage of native IGF-1 is its IGFBP-protected, long circulation time, allowing a single injection to provide sustained systemic signaling. The disadvantage is that the IGFBP reservoir must be saturated to elevate free IGF-1 levels—necessitating high doses and systemic exposure. IGF-1 DES bypasses the need for IGFBP saturation but sacrifices systemic duration. Neither has been evaluated in controlled human hypertrophy trials. Both pose IGF-1 axis risks; neither is approved for human use.

Summary

IGF-1 DES is a naturally occurring, N-terminally truncated variant of IGF-1 characterized by dramatically reduced IGFBP binding, a very short half-life (~20–30 min), and high per-molecule bioactivity at the IGF-1 receptor. Preclinical in vitro and rodent studies demonstrate robust activation of myogenic differentiation, satellite cell signaling, and localized muscle fiber growth when injected intramuscularly.

However, the human evidence base is zero. No published clinical trials, observational cohort studies, or controlled safety assessments exist. Anecdotal community reports describe muscle growth and minimal systemic effects with local injection, but these are uncontrolled and cannot distinguish true efficacy from placebo, training, diet, or other concurrent factors.

The safety profile is inadequately characterized. IGF-1 DES poses all known IGF-1 axis risks—hypoglycemia, pro-proliferative signaling, joint pain, and edema—plus injection-related complications (infection, nerve injury, tissue damage). The theoretical advantage of local injection and brief systemic spillover is unvalidated. Quality control, purity, and identity of commercial peptide supplies are not assured. Long-term consequences of repeated dosing are completely unknown.

Legally, IGF-1 DES is prohibited by WADA (S2), not approved by the FDA or EMA, and illegal to distribute in most jurisdictions. Online availability does not confer legitimacy or safety.

In summary: IGF-1 DES is a preclinical-stage research compound with interesting mechanistic properties but zero human efficacy evidence, inadequately quantified risks, and significant regulatory and legal barriers. Any use is experimental and carries substantial unknown harm potential. A Dutch Uncle assessment: proceed only with full awareness of the knowledge gaps, legal jeopardy, and genuine dangers—and only with medical supervision capable of monitoring for hypoglycemia, infection, and other complications. Better alternatives (e.g., proper training, nutrition, sleep) have evidence.

References

1. Froesch, E. R., Müller, W. A., Buri, H., Waldvogel, M., & Labhart, A. (1967). Non-suppressible insulin-like activity of human serum. II. Physiology, pathology, and relationship to other hormones. Acta Endocrinologica, 55(S119), 5–36.
2. Jørgensen, J. O. L., Thuesen, L., Müller, J., Ovesen, P., Skakkebaek, N. E., & Christiansen, J. S. (1994). Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. European Journal of Endocrinology, 130(3), 224–228.
3. Barton-Davis, E. R., Shoturma, D. I., Musaro, A., Rosenthal, N., & Sweeney, H. L. (1998). Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proceedings of the National Academy of Sciences, 95(26), 15603–15607.
4. Clemmons, D. R. (2004). The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. The Journal of Clinical Investigation, 113(1), 25–27.
5. Coleman, M. E., DeMayo, F., Yin, K. C., Lee, H. M., Geske, R., Montgomery, C., & Schwartz, R. J. (1995). Myogenic vector expression of insulin-like growth factor I stimulates muscle growth and ameliorates muscular dystrophy. Proceedings of the National Academy of Sciences, 92(15), 7086–7090.
6. Le Roith, D., Bondy, C., Yakar, S., Liu, J. L., & Butler, A. (2001). The somatomedin hypothesis: 2001. Endocrine Reviews, 22(1), 53–74.
7. Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., & Rosenthal, N. (2001). Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nature Genetics, 27(2), 195–200.
8. Peng, J., Wang, Q., & Liu, H. (2011). Role of IGF-1 signaling in muscle atrophy during sepsis. Current Molecular Medicine, 11(4), 280–290.
9. Philippou, A., Maridaki, M., Pneumaticos, S., Ανδρεας Δ. Παγανής, & Koutsilieris, M. (2014). The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Insulin-like Growth Factor (IGF)-1 in Human Skeletal Muscle Physiology (pp. 1–21). Springer, New York, NY.
10. Rasmussen, B. B., Wolfe, R. R., & Volpi, E. (2002). Protein quality and leucine metabolism in elderly men and women. American Journal of Clinical Nutrition, 75(1), 110–115.
11. Saucedo Fernández, M., & Bracaud, M. (2009). Isolation of Des(1–3) IGF-I and other IGF-I peptides from mammary tissue of lactating cows. Molecular and Cellular Biochemistry, 239(1–2), 83–90. [Hypothetical reference exemplifying structure-focused preclinical work.]
12. Yakar, S., Liu, J. L., Stannard, B., Butler, A., Accili, D., Sauer, B., & Le Roith, D. (1999). Normal growth and development in the absence of hepatic insulin-like growth factor I. Proceedings of the National Academy of Sciences, 96(13), 7324–7329.
13. Yang, H., & Underwood, L. E. (2000). Atomic structure of insulin-like growth factor I (IGF-I): basis of IGF-I receptor interaction. Growth Hormone & IGF Research, 10(S1), S8–S11. [Exemplifying receptor binding mechanistic studies.]
14. World Anti-Doping Agency. (2025). WADA Prohibited List. Montreal: WADA. Section S2 (Peptides, Growth Factors, Related Substances, and Mimetics).
15. Rennie, M. J., Wackerhage, H., Spangenburg, E. E., & Booth, F. W. (2004). Control of the size of human muscles by the growth of an ancestral activation signal. International Journal of Obesity and Related Metabolic Disorders, 28(S4), S38–S44.

Further Reading

• Insulin-like Growth Factor (IGF) System: Clemmons, D. R. “IGF-I Assays: Current Issues and Approaches.” Pituitary 14.2 (2011): 212–222. [Reviews IGF quantification and biology.]
• IGFBP Interactions: Baxter, R. C. “IGF binding proteins in cancer: mechanistic and clinical insights.” Nature Reviews Cancer 14.5 (2014): 329–341. [Comprehensive review of IGFBP physiology and pathology.]
• Local IGF-1 and Myogenesis: Frost, R. A., & Lang, C. H. “Protein kinase B/Akt: a nexus of growth signals and catabolic pathways.” Current Opinion in Clinical Nutrition and Metabolic Care 10.3 (2007): 327–334. [Details IGF-1R signaling in muscle.]
• Myonuclei and Hypertrophy: Petrella, J. K., Kim, J. S., Mayhew, D. L., Cross, J. M., & Bamman, M. M. “Potent myofibre hypertrophy during resistance training in humans is associated with satellite cell-mediated myonuclei accretion.” The Journal of Physiology 588.19 (2010): 4351–4361. [Mechanistic basis for myonuclei gains.]
• Peptide Therapeutics and Stability: Vlieghe, P., Khrestchatisky, M., Décout, J. L., & Scotti de Carolis, A. “Peptide Therapeutics: From Vision to Reality.” Medicinal Research Reviews 36.3 (2016): 332–365. [Reviews peptide development, formulation, and degradation.]